Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Molecular changes in human melanoma metastasis

M R Luca1, M Bar-Eli

  • 1Department of Cell Biology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Histology and Histopathology
|November 12, 1998
PubMed
Summary

Loss of transcription factor AP-2 is crucial for melanoma metastasis. Metastatic melanoma cells lose AP-2, leading to overexpression of MCAM and loss of c-KIT, driving tumor progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Physiological and cognitive responses to cold exposure in 11-12-year-old boys.

American journal of human biology : the official journal of the Human Biology Council·2017
Same author

Mitochondrial oligomers boost glycolysis in cancer stem cells to facilitate blebbishield-mediated transformation after apoptosis.

Cell death discovery·2016
Same author

Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression.

Oncogene·2016
Same author

Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling.

Oncogene·2015
Same author

Cell adhesion: implication in tumor progression.

Minerva medica·2010
Same author

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

British journal of cancer·2008

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Melanoma progression involves transitions from radial to vertical growth phases.
  • Molecular mechanisms driving melanoma metastasis are not fully understood.
  • Tumor suppressor genes p53 and p16/CDKN2 have limited roles in melanoma metastatic potential.

Purpose of the Study:

  • Investigate molecular changes during melanoma progression.
  • Determine the roles of c-KIT and MCAM/MUC-18 in melanoma metastasis.
  • Identify key regulatory factors in melanoma metastatic phenotype acquisition.

Main Methods:

  • Analysis of p53 and p16/CDKN2 gene mutations and abnormalities in melanoma cells.
  • Studying the expression of c-KIT and MCAM/MUC-18 in melanoma cells with varying metastatic potential.
  • Investigating the effects of enforced c-KIT expression and stem cell factor (SCF) exposure on melanoma cell growth and apoptosis.
  • Examining the impact of ectopic MCAM expression on melanoma tumorigenicity.
  • Assessing the regulation of c-KIT and MCAM by the transcription factor AP-2.

Main Results:

  • p53 mutations are infrequent and do not correlate with metastatic potential.
  • p16/CDKN2 abnormalities are common but not essential for metastasis.
  • Metastatic melanoma cells overexpress MCAM and lack c-KIT expression.
  • Enforced c-KIT expression inhibits melanoma growth and metastasis.
  • SCF induces apoptosis in c-KIT-positive melanoma cells.
  • Ectopic MCAM expression enhances melanoma tumorigenicity and metastasis.
  • Both c-KIT and MCAM are regulated by AP-2; metastatic cells lack AP-2.

Conclusions:

  • Loss of AP-2 transcription factor activity is a critical event in human melanoma progression.
  • The interplay between c-KIT and MCAM, regulated by AP-2, is central to melanoma metastasis.
  • Targeting AP-2 or its downstream effectors may offer therapeutic strategies for metastatic melanoma.

Related Experiment Videos